4 research outputs found
A Bismuth Metal–Organic Framework as a Contrast Agent for X‑ray Computed Tomography
No full textA new
bismuth metal–organic framework (MOF), bismuth-NU-901
(Bi-NU-901), featuring the scu topology and a pore
with a diameter of ∼11 Å, was solvothermally synthesized,
and its use as an X-ray computed tomography (CT) contrast agent was
tested. X-ray CT is a common diagnostic method used in the medical
field. Inside the body, contrast media enhance the distinction between
tissues and organs of similar density. Bi-NU-901 consists of eight
connected Bi6 nodes and tetratopic 1,3,5,8-(p-benzoate)pyrene linkers (TBAPy). Numerous material characterization
studies including powder X-ray diffraction (PXRD), scanning transmission
electron microscopy (STEM), and DFT pore size distribution support
the scu structure. Additionally, given the framework’s
high density of nontoxic heavy atoms, Bi-NU-901 was evaluated as an
X-ray computed tomography (CT) agent. Importantly, in vitro studies revealed this new bismuth MOF demonstrates ∼7 times
better contrast intensity compared to a zirconium MOF featuring the
same topology and ∼14 times better contrast than a commercially
available CT contrast agent. These results suggest bismuth MOFs may
be promising CT contrast agents
Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma
No full textAims
Mobile Airways Sentinel NetworK (MASK) belongs to the Fondation Partenariale MACVIA-LR of Montpellier, France and aims to provide an active and healthy life to rhinitis sufferers and to those with asthma multimorbidity across the life cycle, whatever their gender or socio-economic status, in order to reduce health and social inequities incurred by the disease and to improve the digital transformation of health and care. The ultimate goal is to change the management strategy in chronic diseases.
Methods
MASK implements ICT technologies for individualized and predictive medicine to develop novel care pathways by a multi-disciplinary group centred around the patients.
Stakeholders
Include patients, health care professionals (pharmacists and physicians), authorities, patient’s associations, private and public sectors.
Results
MASK is deployed in 23 countries and 17 languages. 26,000 users have registered.
EU grants (2018)
MASK is participating in EU projects (POLLAR: impact of air POLLution in Asthma and Rhinitis, EIT Health, DigitalHealthEurope, Euriphi and Vigour).
Lessons learnt
(i) Adherence to treatment is the major problem of allergic disease, (ii) Self-management strategies should be considerably expanded (behavioural), (iii) Change management is essential in allergic diseases, (iv) Education strategies should be reconsidered using a patient-centred approach and (v) Lessons learnt for allergic diseases can be expanded to chronic diseases
